-
Something wrong with this record ?
IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis
M. Petržalka, E. Meluzínová, J. Libertínová, H. Mojžišová, J. Hanzalová, P. Ročková, M. Elišák, S. Kmetonyová, J. Šanda, O. Sobek, P. Marusič
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Biomarkers cerebrospinal fluid MeSH
- Chitinases metabolism MeSH
- Chronic Disease MeSH
- Interleukin-2 metabolism MeSH
- Interleukin-6 metabolism MeSH
- Humans MeSH
- Recurrence MeSH
- Multiple Sclerosis * cerebrospinal fluid diagnosis drug therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: The possibility to better predict the severity of the disease in a patient newly diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and lead to better clinical outcomes. Prognostic biomarkers are highly needed. OBJECTIVE: To assess the prognostic value of intrathecal IgM synthesis, cerebrospinal fluid and serum IL-2, IL-6, IL-10, chitinase 3-like 2 and neurofilament heavy chains obtained early after the onset of the disease. METHODS: 58 patients after the first manifestation of multiple sclerosis were included. After the initial diagnostic assessment including serum and cerebrospinal fluid biomarkers, all patients initiated therapy with either glatiramer acetate, teriflunomide, or interferon beta. To assess the evolution of the disease, we followed the patients clinically and with MRI for two years. RESULTS: The IL-2:IL-6 ratio (both in cerebrospinal fluid) <0.48 (p = 0.0028), IL-2 in cerebrospinal fluid ≥1.23pg/ml (p = 0.026), and chitinase 3-like 2 in cerebrospinal fluid ≥7900pg/ml (p = 0.033), as well as baseline EDSS ≥1.5 (p = 0.0481) and age <22 (p = 0.0312), proved to be independent markers associated with shorter relapse free intervals. CONCLUSION: The IL-2:IL-6 ratio, IL-2, and chitinase 3-like 2 (all in cerebrospinal fluid) might be of value as prognostic biomarkers in early phases of multiple sclerosis.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017943
- 003
- CZ-PrNML
- 005
- 20220804134456.0
- 007
- ta
- 008
- 220720s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0270607 $2 doi
- 035 __
- $a (PubMed)35759479
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Petržalka, Marko $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000309122656
- 245 10
- $a IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis / $c M. Petržalka, E. Meluzínová, J. Libertínová, H. Mojžišová, J. Hanzalová, P. Ročková, M. Elišák, S. Kmetonyová, J. Šanda, O. Sobek, P. Marusič
- 520 9_
- $a BACKGROUND: The possibility to better predict the severity of the disease in a patient newly diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and lead to better clinical outcomes. Prognostic biomarkers are highly needed. OBJECTIVE: To assess the prognostic value of intrathecal IgM synthesis, cerebrospinal fluid and serum IL-2, IL-6, IL-10, chitinase 3-like 2 and neurofilament heavy chains obtained early after the onset of the disease. METHODS: 58 patients after the first manifestation of multiple sclerosis were included. After the initial diagnostic assessment including serum and cerebrospinal fluid biomarkers, all patients initiated therapy with either glatiramer acetate, teriflunomide, or interferon beta. To assess the evolution of the disease, we followed the patients clinically and with MRI for two years. RESULTS: The IL-2:IL-6 ratio (both in cerebrospinal fluid) <0.48 (p = 0.0028), IL-2 in cerebrospinal fluid ≥1.23pg/ml (p = 0.026), and chitinase 3-like 2 in cerebrospinal fluid ≥7900pg/ml (p = 0.033), as well as baseline EDSS ≥1.5 (p = 0.0481) and age <22 (p = 0.0312), proved to be independent markers associated with shorter relapse free intervals. CONCLUSION: The IL-2:IL-6 ratio, IL-2, and chitinase 3-like 2 (all in cerebrospinal fluid) might be of value as prognostic biomarkers in early phases of multiple sclerosis.
- 650 _2
- $a biologické markery $x mozkomíšní mok $7 D015415
- 650 _2
- $a chitinasy $x metabolismus $7 D002688
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interleukin-2 $x metabolismus $7 D007376
- 650 _2
- $a interleukin-6 $x metabolismus $7 D015850
- 650 12
- $a roztroušená skleróza $x mozkomíšní mok $x diagnóza $x farmakoterapie $7 D009103
- 650 _2
- $a recidiva $7 D012008
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Meluzínová, Eva $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Libertínová, Jana $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Mojžišová, Hana $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Hanzalová, Jitka $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic $u Second Faculty of Medicine, Department of Immunology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Ročková, Petra $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Elišák, Martin $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Kmetonyová, Silvia $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Šanda, Jan $u Second Faculty of Medicine, Department of Radiology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Sobek, Ondřej $u Topelex sro, Laboratory for CSF, Neuroimmunology, Pathology and Special Diagnostics, Prague, Czech Republic
- 700 1_
- $a Marusič, Petr $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 17, č. 6 (2022), s. e0270607
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35759479 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134450 $b ABA008
- 999 __
- $a ok $b bmc $g 1821845 $s 1169186
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 17 $c 6 $d e0270607 $e 20220627 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20220720
